CANSINOBIO Reports Zero Share Capital Changes for July 2026; 860,000 H-Share Options Remain Outstanding

Bulletin Express08-04

CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 31 July 2026, confirming stability across both its Hong Kong-listed H shares and Shanghai STAR Market A shares.

Authorised and Issued Share Capital • Authorised share capital stood unchanged at RMB 247.04 million, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1. • Issued share counts matched authorised levels, with no new shares issued, cancelled or repurchased during the month. Treasury share balances remained nil.

Public Float Compliance • The company affirmed compliance with Hong Kong Main Board Rule 13.32D, maintaining at least 5% public float for its H-share class.

Equity Incentive Plans • H-Share Options: 860,000 options under the “2025 Core Management H Share Option Scheme” remained outstanding; no exercises or cancellations occurred in July. • A-Share Restricted Stock: Up to 2.05 million A shares may still be issued under the “2025 Restricted A Share Incentive Scheme,” with no grants or transfers executed during the month.

Capital Structure Summary (31 July 2026) • Total authorised / issued shares: 247.04 million • Treasury shares: 0 • Potential dilution from outstanding H-share options: 0.35% of current issued H-share base. • Additional potential issuance under A-share restricted scheme: 1.80% of current issued A-share base.

Management Confirmation Joint Company Secretary Jin Cui submitted the return, which indicates no other outstanding convertibles, warrants or share repurchase activities for the reporting month.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157392547?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157392547","market":"hk","top_or_hot":-1,"title":"CANSINOBIO Reports Zero Share Capital Changes for July 2026; 860,000 H-Share Options Remain Outstanding","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 31 July 2026, confirming stability across both its Hong Kong-listed H shares and Shanghai STAR Market A shares.</p>\n<p>Authorised and Issued Share Capital  \n• Authorised share capital stood unchanged at RMB 247.04 million, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1.  \n• Issued share counts matched authorised levels, with no new shares issued, cancelled or repurchased during the month. Treasury share balances remained nil.</p>\n<p>Public Float Compliance  \n• The company affirmed compliance with Hong Kong Main Board Rule 13.32D, maintaining at least 5% public float for its H-share class.</p>\n<p>Equity Incentive Plans  \n• H-Share Options: 860,000 options under the “2025 Core Management H Share Option Scheme” remained outstanding; no exercises or cancellations occurred in July.  \n• A-Share Restricted Stock: Up to 2.05 million A shares may still be issued under the “2025 Restricted A Share Incentive Scheme,” with no grants or transfers executed during the month.</p>\n<p>Capital Structure Summary (31 July 2026)  \n• Total authorised / issued shares: 247.04 million  \n• Treasury shares: 0  \n• Potential dilution from outstanding H-share options: 0.35% of current issued H-share base.  \n• Additional potential issuance under A-share restricted scheme: 1.80% of current issued A-share base.</p>\n<p>Management Confirmation  \nJoint Company Secretary Jin Cui submitted the return, which indicates no other outstanding convertibles, warrants or share repurchase activities for the reporting month.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO Reports Zero Share Capital Changes for July 2026; 860,000 H-Share Options Remain Outstanding</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO Reports Zero Share Capital Changes for July 2026; 860,000 H-Share Options Remain Outstanding\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-04 17:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 31 July 2026, confirming stability across both its Hong Kong-listed H shares and Shanghai STAR Market A shares.</p>\n<p>Authorised and Issued Share Capital  \n• Authorised share capital stood unchanged at RMB 247.04 million, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1.  \n• Issued share counts matched authorised levels, with no new shares issued, cancelled or repurchased during the month. Treasury share balances remained nil.</p>\n<p>Public Float Compliance  \n• The company affirmed compliance with Hong Kong Main Board Rule 13.32D, maintaining at least 5% public float for its H-share class.</p>\n<p>Equity Incentive Plans  \n• H-Share Options: 860,000 options under the “2025 Core Management H Share Option Scheme” remained outstanding; no exercises or cancellations occurred in July.  \n• A-Share Restricted Stock: Up to 2.05 million A shares may still be issued under the “2025 Restricted A Share Incentive Scheme,” with no grants or transfers executed during the month.</p>\n<p>Capital Structure Summary (31 July 2026)  \n• Total authorised / issued shares: 247.04 million  \n• Treasury shares: 0  \n• Potential dilution from outstanding H-share options: 0.35% of current issued H-share base.  \n• Additional potential issuance under A-share restricted scheme: 1.80% of current issued A-share base.</p>\n<p>Management Confirmation  \nJoint Company Secretary Jin Cui submitted the return, which indicates no other outstanding convertibles, warrants or share repurchase activities for the reporting month.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1157392547","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157392547","pubTimestamp":1785834525,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 31 July 2026, confirming stability across both its Hong Kong-listed H shares and Shanghai STAR Market A shares....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物报告 2026 年 7 月股本零变动；仍有 86 万份 H 股期权未行使","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 31 July 2026, confirming stability across both its Hong Kong-listed H shares and Shanghai STAR Market A shares.\nAuthorised and Issued Share Capital  \n• Authorised share capital stood unchanged at RMB 247.04 million, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1.  \n• Issued share counts matched authorised levels, with no new shares issued, cancelled or repurchased during the month. Treasury share balances remained nil.\nPublic Float Compliance  \n• The company affirmed compliance with Hong Kong Main Board Rule 13.32D, maintaining at least 5% public float for its H-share class.\nEquity Incentive Plans  \n• H-Share Options: 860,000 options under the “2025 Core Management H Share Option Scheme” remained outstanding; no exercises or cancellations occurred in July.  \n• A-Share Restricted Stock: Up to 2.05 million A shares may still be issued under the “2025 Restricted A Share Incentive Scheme,” with no grants or transfers executed during the month.\nCapital Structure Summary (31 July 2026)  \n• Total authorised / issued shares: 247.04 million  \n• Treasury shares: 0  \n• Potential dilution from outstanding H-share options: 0.35% of current issued H-share base.  \n• Additional potential issuance under A-share restricted scheme: 1.80% of current issued A-share base.\nManagement Confirmation  \nJoint Company Secretary Jin Cui submitted the return, which indicates no other outstanding convertibles, warrants or share repurchase activities for the reporting month.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157392547","isCrawlerRequest":true}